t the same life as before cancer." Recently, however, it stopped working. Now on a new drug, she's also taking part in a first-of-its-kind study by the Addario Lung Cancer Medical Institute that's looking specifically at the DNA of young people with lung cancer. The hope is to identify additional mutations that could point the way to b

ected by FoundationOne could benefit from crizotinib, an approved inhibitor of ALK. Clinical trial updates: • In July, the company partnered with the Addario Lung Cancer Medical Institute and Bonnie 1. Addario lung Cancer Foundation to launch the Genomics of Young Lung Cancer clinical trial, a first of its kind, multi-center, interna